Gilead's Rohini Mehtani, Ph.D. Reflects on The Importance of ASH21 | News Direct

Gilead's Rohini Mehtani, Ph.D. Reflects on The Importance of ASH21

News release by Gilead Sciences

facebook icon linkedin icon twitter icon pinterest icon email icon Northampton, MA | January 04, 2022 01:31 PM Eastern Standard Time

As ASH21 wraps up, Gilead’s Rohini Mehtani, Ph.D. reflects on the importance of the meeting, particularly for people living with higher-risk myelodysplastic syndrome.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. 

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com